Featured Article: New therapeutic strategies to treat human cancers expressing mutant p53 proteins
A commonly mutated gene found in human cancers is TP53. As TP53 is a tumor suppressor gene, mutations in it can result in the production of mutant p53 proteins exhibiting oncogenic functions which can cause increased chemoresistance, uncontrolled cell proliferation, interference with normal tissue architecture and the promotion of metastasis, migration and invasion, to name a few.
In this review, G. Blandino and S. Di Agostino discuss and summarize the recent advances made in cancer research towards the treatment of cancers expressing mutant p53 proteins. In particular, inhibitors of signaling pathways that are controlled by the mutant p53 proteins are highlighted, including how these inhibitors can be applied clinically as a potential therapeutic strategy for the treatment of cancer.
Click here to access the full article.
Click here to access all of the reviews published to date in Journal of Experimental & Clinical Cancer Research.
Aims and scope
Journal of Experimental & Clinical Cancer Research is an online peer-reviewed journal that provides a high-quality forum for all aspects of basic, clinical and translational work in oncology.
Please click here to read more.
Articles
Meeting reports now accepted
Journal of Experimental & Clinical Cancer Research now welcomes the submission of Meeting reports to help showcase novel developments presented at meetings and conferences.
Please click here for more information on the article types accepted by Journal of Experimental & Clinical Cancer Research.
Editor-in-Chief
Mauro Castelli, Regina Elena National Cancer Institute, Italy
If you would like to contact Journal of Experimental & Clinical Cancer Research, please send an email to:
Call for papers: Translational oncology
We are pleased to announce that a number of BioMed Central journals have come together to create a new cross-journal series on translational oncology.
Guest Edited by Prof Tommaso Dragani (Fondazione IRCCS Istituto Nazionale dei Tumori, Italy), the series is now accepting submissions of research articles that provide important developments in cancer research. Preclinical studies should provide a significant advance in knowledge, and have clear potential for strong clinical impact. For more information on the series, please click here to visit the series page.
Archival content
Journal of Experimental & Clinical Cancer Research has been publishing since 1982. Prior to publishing with BioMed Central from 2008, Journal of Experimental & Clinical Cancer Research was published in print. For enquiries about previous content, please contact us on:
Reviewer Acknowledgement
The editorial team of Journal of Experimental & Clinical Cancer Research would like to thank all of our reviewers who have contributed to the journal.
Click here to visit the Reviewer acknowledgements page.
Advertisement
-
-
Owned by the Association for International Promotion & Study in Tumors (APSIT)
-
Official journal of the Regina Elena National Cancer Institute, Italy
-
- Editorial Board
- Sign up for article alerts and news from this journal
Follow
2017 Journal Metrics
-
Speed
30 days from submission to first decision
89 days from submission to acceptance
14 days from acceptance to publicationCitation Impact
6.217 - 2-year Impact Factor
5.280 - 5-year Impact Factor
1.350 - Source Normalized Impact per Paper (SNIP)
2.000 - SCImago Journal Rank (SJR)Usage
599,727 Downloads
364 Altmetric Mentions
Advertisement
